Opendata, web and dolomites

PARADIGM SIGNED

Patients Active in Research and Dialogues for an Improved Generation of Medicines: Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "PARADIGM" data sheet

The following table provides information about the project.

Coordinator
FORUM EUROPEEN DES PATIENTS (FPE) 

Organization address
address: RUE DICKS 14
city: LUXEMBOURG
postcode: 1417
website: http://www.eu-patient.eu/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Luxembourg [LU]
 Project website https://imi-paradigm.eu/
 Total cost 9˙100˙277 €
 EC max contribution 4˙498˙931 € (49%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2016-10-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2018
 Duration (year-month-day) from 2018-03-01   to  2020-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FORUM EUROPEEN DES PATIENTS (FPE) LU (LUXEMBOURG) coordinator 702˙516.00
2    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 621˙592.00
3    THE SYNERGIST BE (BRUXELLES) participant 543˙828.00
4    SYNAPSE RESEARCH MANAGEMENT PARTNERS SL ES (MADRID) participant 473˙500.00
5    EURORDIS - EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION FR (Paris) participant 463˙597.00
6    STICHTING VU NL (AMSTERDAM) participant 458˙437.00
7    EUROPEAN AIDS TREATMENT GROUP EV DE (DUSSELDORF) participant 381˙750.00
8    ALZHEIMER EUROPE LU (LUXEMBOURG) participant 248˙500.00
9    EUROPEAN FORUM FOR GOOD CLINICAL PRACTICE BE (BRUSSELS) participant 198˙000.00
10    INSTITUTO ARAGONES DE CIENCIAS DE LA SALUD ES (ZARAGOZA) participant 181˙086.00
11    FUNDACIO SANT JOAN DE DEU ES (Esplugues de Llobregat) participant 176˙125.00
12    AGENZIA ITALIANA DEL FARMACO IT (ROMA) participant 50˙000.00
13    ALEXION SERVICES EUROPE SPRL BE (BRUSSELS) participant 0.00
14    AMGEN LIMITED UK (CAMBRIDGE) participant 0.00
15    BAYER AKTIENGESELLSCHAFT DE (Leverkusen) participant 0.00
16    COVANCE LABORATORIES LTD UK (HARROGATE) participant 0.00
17    Eli Lilly and Company Limited UK (Basingstoke) participant 0.00
18    F. HOFFMANN-LA ROCHE AG CH (BASEL) participant 0.00
19    FEDERATION EUROPEENNE D'ASSOCIATIONS ET D'INDUSTRIES PHARMACEUTIQUES BE (BRUXELLES) participant 0.00
20    GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. UK (BRENTFORD) participant 0.00
21    GRUNENTHAL GMBH DE (AACHEN) participant 0.00
22    H. LUNDBECK AS DK (VALBY) participant 0.00
23    HEALTH TECHNOLOGY ASSESSMENT INTERNATIONAL SOCIETY CA (EDMONTON) participant 0.00
24    INSTITUT DE RECHERCHES INTERNATIONALES SERVIER FR (SURESNES) participant 0.00
25    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
26    MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN DE (DARMSTADT) participant 0.00
27    MERCK SHARP & DOHME CORP US (WHITEHOUSE STATION NJ) participant 0.00
28    NOVARTIS PHARMA AG CH (BASEL) participant 0.00
29    NOVO NORDISK A/S DK (BAGSVAERD) participant 0.00
30    PFIZER LIMITED UK (SANDWICH) participant 0.00
31    SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT FR (Chilly Mazarin) participant 0.00
32    THE ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY UK (LONDON) participant 0.00
33    UCB BIOPHARMA SRL BE (BRUXELLES) participant 0.00
34    VERBAND FORSCHENDER ARZNEIMITTELHERSTELLER EV DE (Berlin) participant 0.00

Map

 Project objective

PARADIGM will provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engagement (PE) and demonstrates the ‘return on the engagement’ for all players. Much needed processes and tools for three key decision-making points (research priority setting, design of clinical trials and early dialogue) will be developed by consensus. Building on advances at international level, PARADIGM will integrate the needs, perspectives and expectations of all actors (including vulnerable populations) involved and will also produce a stakeholder-tailored set of metrics to measure the impact of PE. PARADIGM will deliver to the community, recommendations and tools to support the implementation of PE, leveraging pre-existing resources. These will address capacity and capability questions, managing potential conflict of interest, the compensation of individuals and organisations, and the ethics of engagement. A targeted communication, dissemination and engagement strategy will promote the endorsement of the outputs for their integration in existing structures. PARADIGM will develop a strategy for sustaining the long-term implementation of PE resources aimed at structuring and supporting the community. This will be a game-changer, addressing fundamental gaps and creating real assets to ensure the sustainability of the PE ecosystem in the years to come. PARADIGM has a common vision and values-base, and is a highly innovative, consensus-oriented, and experienced consortium, comprising pan-European leaders in patient engagement, academia, SMEs, health professionals, pharmaceutical and biotech companies, pharmaceutical corporate associations, and representatives of competent authorities, all bringing complementary know-how to partner with industry, and a strong commitment to transform patient engagement in Europe.

 Deliverables

List of deliverables.
Ethical Framework Documents, reports 2020-04-11 08:14:50
Data Management Plan Documents, reports 2020-04-11 08:14:50
Communication and external engagement plan Documents, reports 2020-04-11 08:14:49
Review existing methods for monitoring and evaluation patient engagement Documents, reports 2020-04-11 08:14:49
Report on the first open Patient Engagement Forum Documents, reports 2020-04-11 08:14:48
Survey analysis report on stakeholder-specific preferences, needs and expectations Documents, reports 2020-04-11 08:14:50
Digital assets including website Websites, patent fillings, videos etc. 2020-04-11 08:14:49

Take a look to the deliverables list in detail:  detailed list of PARADIGM deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PARADIGM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PARADIGM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

AB-DiRecT (2019)

Antibiotic Distribution and Recovery in Tissue

Read More